Futibatinib Safe and Effective in Patients with Advanced or Metastatic Intrahepatic Cholangiocarcinoma and FGFR2 Fusions

October 2020, Vol 1, No 2

Two phase 2 studies of futibatinib, a highly selective irreversible fibroblast growth factor receptor (FGFR)1-4 inhibitor, analyzed data from the FOENIX-CCA2 clinical trial and were presented at the 2020 virtual meeting of the European Society for Medical Oncology (ESMO).

FOENIX-CCA2 is an ongoing, global, open-label phase 2 clinical trial that enrolled patients with locally advanced or metastatic unresectable intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements. Approximately 10% to 20% of patients with CCA have FGFR2 fusions.

Of the 103 patients participating in FOENIX-CCA2, 67 patients were included in each of the 2 studies presented at ESMO. The first study analyzed efficacy and safety data, and the second study evaluated quality-of-life (QOL) outcomes. In 2018, the FDA granted futibatinib an orphan drug status.

Efficacy and Safety in FOENIX-CCA2

In the first study, John A. Bridgewater, PhD, FRCP, Professor of Medical Oncology, Department of Medical Oncology, University College London Cancer Institute, England, and colleagues presented data from the FOENIX-CCA2 clinical trial for 67 patients who received futibatinib and had a minimum of 6-month follow-up. Most (82%) of these patients had FGFR2 fusions.

The primary end point of the study was the objective response rate (ORR), as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 criteria, which was confirmed by a second tumor assessment 4 to 6 weeks after the initial response. The secondary end points included the duration of response, disease control rate, progression-free survival, and safety.

The ORR with futibatinib was 37.3%, with a median duration of response of 8.3 months; and 37% of the patients are still receiving treatment. The subgroup analysis revealed that patients aged ≥65 years had a better ORR than younger patients under age 65 years (57.1% vs 32.1%, respectively), and female patients had a better ORR than male patients (43.6% vs 28.6%, respectively).

The adverse events reported were consistent with those seen in other FGFR inhibitors. Of note, patients who responded to treatment with futibatinib had higher phosphate levels than nonresponders. This is noteworthy, because the most common adverse event in the patients who received futibatinib was hyperphosphatemia.

A phase 3 clinical trial of futibatinib versus gemcitabine and cisplatin for the first-line treatment of patients with intrahepatic CCA and FGFR2 rearrangements is underway.

Quality-of-Life Study in FOENIX-CCA2

The second study examined the health-related QOL data from the FOENIX-CCA2 clinical trial. This is the first report of QOL data for an FGFR inhibitor in patients with intrahepatic CCA. Juan W. Valle, MB ChB, MSc, FRCP, Division of Cancer Sciences, University of Manchester, England, and colleagues collected patient-reported outcomes (PROs) from the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EuroQol-5D (EQ-5D-3L) QOL instruments.

The EORTC QLQ-C30 is composed of 5 multi-item scales (ie, physical, role, social, emotional, and cognitive functioning) and 9 single items (ie, pain, fatigue, financial impact, appetite loss, nausea/vomiting, diarrhea, constipation, sleep disturbance, and QOL). The EQ-5D-3L is a QOL measure with 1 question for each of 5 dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

A total of 67 patients were included in the interim analysis, of whom 57 (85%) patients had PROs available. The investigators collected PROs at screening, then at cycles 2 and 4, then every 3 cycles, and at the end of treatment. The mean QLQ-C30 score was sustained and was stable in terms of individual function and symptom measures from baseline through treatment cycle 13 (ie, 273 days) of futibatinib.

The only clinically meaningful increase in QLQ-C30 score (ie, an increase of ≥10 points) was a worsening of constipation at cycles 2 and 4 (+12.4 and +10.7 points, respectively). The mean EQ-5D-3L score demonstrated an increasing trend from baseline to cycle 13, which suggests that patients had improved QOL and health.

Overall, the PROs from the FOENIX-CCA2 are encouraging, the investigators concluded, noting that treatment with futibatinib does not adversely affect patients’ QOL.

Related Items

The Impact of mFOLFOX Chemotherapy in Conjunction with Active Symptom Control on Patient QOL: The ABC-06 Trial
Web Exclusives
Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
Derazantinib Shows Clinical Efficacy in the Treatment of iCCA in Patients with Genetically Aberrant FGFR2
Web Exclusives
Data from the FIDES-01 clinical trial showed encouraging results for derazantinib as a second-line treatment for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions, mutations, or amplification.
Real-World Evidence for Liquid Biopsy to Identify Molecular Alterations
Web Exclusives
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.
FGFR Inhibitor RLY-4008 Shows Promise in Treating Metastatic CCA
Web Exclusives
Early data from the ReFocus trial indicated that the highly selective FGFR2 inhibitor RLY-4008 may be an effective new treatment for cholangiocarcinoma in patients with FGFR2 fusions or rearrangements.
Nanoliposomal Irinotecan Combination Therapy Falls Short in Metastatic BTC
Web Exclusives
The NALIRICC study compared the efficacy of nanoliposomal irinotecan plus 5-fluorouracil (5-FU) plus leucovorin (LV) with 5-FU plus LV on progression-free and overall survival in patients with biliary tract cancer.
Tislelizumab as Part of a Conversion Therapy Regimen for Potentially Resectable Biliary Tract Cancers
Web Exclusives
A phase 2 study found that the combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin showed promise as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer, making curative surgery a possibility for some patients.
Additional 6-Month Follow-up from the TOPAZ-1 Study Comparing Durvalumab with Placebo plus Gem/Cis in Patients with Advanced BTC
Web Exclusives
Updated overall survival (OS) and safety data from the TOPAZ-1 study revealed improved median OS for the full patient population as well as subgroup analyses and an adverse event profile consistent with previously reported data.
Immune-Related Adverse Events in the TOPAZ-1 Study of Durvalumab or Placebo plus GemCis in Advanced BTC
Web Exclusives
Analysis of the safety population in the TOPAZ-1 trial in patients with biliary tract cancer revealed that immune-related adverse events were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.
CCA Summit Live from ESMO 2022
By Juan W. Valle, MB ChB, MSc, FRCP
On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.
Key Abstracts Presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting
By Richard Kim, MD
Richard Kim, MD, from the Moffitt Cancer Center, University of South Florida College of Medicine, provides expert commentary on key abstracts and posters presented at the 2021 annual meeting of the European Society for Medical Oncology. Dr Kim will highlight new data from 11 presentations on interventional modalities for patients with cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: